Redhill Biopharma Ltd. (RDHL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RDHL SEC filings page.
Redhill Biopharma Ltd. (RDHL) reported $286K in revenue for fiscal year 2025, down 96.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has nearly disappeared, but cash consumption persists, leaving the company dependent on financing and a stretched short-term balance sheet.
Revenue fell96.4% to$286K in FY2025, while operating cash flow remained near its FY2024 level. That divergence suggests the company’s cost base did not flex with activity, making accounting results a weak guide to cash needs.
Liquidity is structurally tight: FY2025 current assets were
The earnings line is a poor proxy for cash needs: FY2025 reported a net loss of
Financial Health Signals
Redhill Biopharma Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Redhill Biopharma Ltd. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Redhill Biopharma Ltd. reported a net loss of $429K while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Redhill Biopharma Ltd. generated $286K in revenue in fiscal year 2025. This represents a decrease of 96.4% from the prior year.
Redhill Biopharma Ltd. reported a net loss of $429K in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Redhill Biopharma Ltd. earned $0.00 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Redhill Biopharma Ltd. recorded an outflow of $9.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Redhill Biopharma Ltd. held $4.0M in cash against $900K in long-term debt as of fiscal year 2025, with $19.2M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Redhill Biopharma Ltd.'s ROE was -10.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Redhill Biopharma Ltd. invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 44.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
RDHL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $286K-96.4% | $8.0M+23.2% | $6.5M-89.4% | $61.8M-27.9% | $85.8M+33.2% | $64.4M+923.0% | $6.3M-24.7% | $8.4M+108.6% | $4.0M+3867.3% | $101K+3266.7% | $3K |
| Cost of Revenue | N/A | $3.2M-7.7% | $3.5M-89.6% | $33.3M-32.5% | $49.4M+33.9% | $36.9M+1533.1% | $2.3M-20.4% | $2.8M+33.4% | $2.1M | N/A | N/A |
| Gross Profit | N/A | $4.9M+58.0% | $3.1M-89.2% | $28.5M-21.7% | $36.4M+32.3% | $27.5M+581.2% | $4.0M-27.0% | $5.5M+193.6% | $1.9M+1762.4% | $101K+3266.7% | $3K |
| R&D Expenses | N/A | $1.6M-55.0% | $3.5M-51.5% | $7.3M-75.3% | $29.5M+78.9% | $16.5M-5.3% | $17.4M-29.9% | $24.9M-24.6% | $33.0M+30.6% | $25.2M+42.0% | $17.8M |
| Operating Income | N/A | -$14.6M-215.7% | $12.6Mn/m | -$42.8Mn/m | -$81.1Mn/m | -$63.7Mn/m | -$43.2Mn/m | -$39.3Mn/m | -$52.0Mn/m | -$30.5Mn/m | -$22.0M |
| Interest Expense | $19K-99.1% | $2.1M-78.6% | $9.6M-77.3% | $42.4M+154.4% | $16.7M+30.6% | $12.8M+2813.0% | $438K+162.3% | $167K+116.9% | $77K-79.5% | $375K+76.9% | $212K |
| Net Income | -$429Kn/m | -$8.3M-134.6% | $23.9Mn/m | -$71.7Mn/m | -$97.7Mn/m | -$76.2Mn/m | -$42.3Mn/m | -$38.8Mn/m | -$45.5Mn/m | -$29.4Mn/m | -$21.1M |
| EPS (Basic) | $0.00n/m | $0.00-100.0% | $0.01 | -$0.12 | -$0.21n/m | -$0.21n/m | -$0.14n/m | -$0.17n/m | -$0.26n/m | -$0.23n/m | -$0.19 |
| EPS (Diluted) | $0.00n/m | $0.00-100.0% | $0.01 | -$0.12 | -$0.21n/m | -$0.21n/m | -$0.14n/m | -$0.17n/m | -$0.26n/m | -$0.24n/m | -$0.19 |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 231M+30.9% | 177M+37.1% | 129M+15.3% | 112M |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA, Income Tax.
RDHL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.3M+40.5% | $18.0M-21.7% | $23.0M-85.5% | $158.9M-12.3% | $181.2M+0.5% | $180.2M+143.2% | $74.1M+18.7% | $62.4M+8.8% | $57.3M-22.7% | $74.2M | N/A |
| Current Assets | $6.5M-45.2% | $11.9M-26.2% | $16.1M-81.2% | $85.9M-3.6% | $89.2M+26.5% | $70.5M+32.5% | $53.2M-6.3% | $56.8M+9.9% | $51.7M-23.8% | $67.8M | N/A |
| Cash & Equivalents | $4.0M-14.0% | $4.6M-17.1% | $5.6M-72.1% | $20.0M-32.3% | $29.5M+0.6% | $29.3M+0.9% | $29.0M+0.1% | $29.0M+76.3% | $16.5M-69.4% | $53.8M+150.0% | $21.5M |
| Short-Term Investments | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | $3.7M-16.8% | $4.4M-60.1% | $11.0M-25.7% | $14.8M+126.9% | $6.5M+246.8% | $1.9M+144.7% | $769K+17.8% | $653K | N/A | N/A |
| Accounts Receivable | N/A | $2.5M-2.0% | $2.6M-92.5% | $34.5M+9.0% | $31.7M+10.5% | $28.7M+2256.5% | $1.2M+26.9% | $958K-37.3% | $1.5M+1443.4% | $99K | N/A |
| Long-Term Investments | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $21.1M-7.3% | $22.7M+8.3% | $21.0M-89.9% | $207.3M+20.3% | $172.3M+3.6% | $166.4M+1080.2% | $14.1M+25.6% | $11.2M-8.6% | $12.3M+6.7% | $11.5M | N/A |
| Current Liabilities | $19.2M-13.5% | $22.2M+11.2% | $20.0M-89.9% | $197.5M+142.4% | $81.5M+11.2% | $73.2M+589.9% | $10.6M+2.3% | $10.4M-12.2% | $11.8M+120.9% | $5.4M | N/A |
| Non-Current Liabilities | $1.9M+269.0% | $503K-49.4% | $995K-89.9% | $9.8M-89.2% | $90.8M-2.5% | $93.1M+2575.7% | $3.5M+312.4% | $844K+88.4% | $448K-92.7% | $6.2M | N/A |
| Long-Term Debt | $900K | N/A | N/A | N/A | $83.6M+2.7% | $81.4M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.3Mn/m | -$4.7M-326.3% | $2.1Mn/m | -$48.4M-645.4% | $8.9M-36.0% | $13.9M-76.9% | $60.0M+17.2% | $51.2M+13.6% | $45.1M-28.1% | $62.7M+4.4% | $60.1M |
| Retained Earnings | -$413.8Mn/m | -$414.8Mn/m | -$407.7Mn/m | -$433.9Mn/m | -$367.9Mn/m | -$280.3Mn/m | -$208.4Mn/m | -$169.1Mn/m | -$132.9Mn/m | -$89.6M | N/A |
Not reported in any period shown, so not listed: Goodwill.
RDHL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.7Mn/m | -$9.4Mn/m | -$35.8Mn/m | -$29.2Mn/m | -$65.0Mn/m | -$48.6Mn/m | -$40.7Mn/m | -$34.5Mn/m | -$44.8Mn/m | -$28.3Mn/m | -$17.8M |
| Capital Expenditures | $5K-44.4% | $9K-18.2% | $11K-94.4% | $198K+72.2% | $115K-71.7% | $406K+141.7% | $168K+630.4% | $23K-84.2% | $146K+71.8% | $85K+507.1% | $14K |
| Free Cash Flow | -$9.7Mn/m | -$9.4Mn/m | -$35.8Mn/m | -$29.4Mn/m | -$65.2Mn/m | -$49.0Mn/m | -$40.9Mn/m | -$34.5Mn/m | -$44.9Mn/m | -$28.3Mn/m | -$17.8M |
| Investing Cash Flow | $1.7Mn/m | -$9K-325.0% | $4K-100.0% | $8.3Mn/m | -$8.1Mn/m | -$35.6M-790.3% | $5.2M-3.5% | $5.4Mn/m | -$18.6M-175.9% | $24.5Mn/m | -$21.2M |
| Financing Cash Flow | $7.3M-13.1% | $8.4M-60.7% | $21.4M+87.2% | $11.5M-84.4% | $73.5M-12.9% | $84.4M+137.6% | $35.5M-15.0% | $41.8M+62.8% | $25.7M-28.8% | $36.0M-34.3% | $54.8M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
RDHL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 60.3%+13.3pp | 47.0%+1.0pp | 46.1%+3.7pp | 42.4%-0.3pp | 42.7%-21.4pp | 64.1%-2.0pp | 66.1%+19.1pp | 46.9%-53.1pp | 100.0%0.0pp | 100.0% |
| Operating Margin | N/A | -181.7% | 193.5% | -69.3%+25.3pp | -94.6%+4.3pp | -99.0% | -686.7% | -470.5% | -1297.0% | -30240.6% | -733400.0% |
| Net Margin | -150.0% | -102.8% | 366.3% | -116.0% | -114.0% | -118.4% | -672.5% | -464.4% | -1136.6% | -29079.2% | -703000.0% |
| Return on Equity | -10.1% | N/A | 1155.9% | N/A | -1101.3%-551.9pp | -549.4%-478.9pp | -70.5%+5.3pp | -75.8%+25.2pp | -101.1%-54.2pp | -46.8%-11.7pp | -35.1% |
| Return on Assets | -1.7%+44.1pp | -45.8%-149.6pp | 103.8%+148.9pp | -45.1%+8.8pp | -53.9%-11.7pp | -42.3%+14.8pp | -57.1%+5.1pp | -62.2%+17.2pp | -79.4%-39.8pp | -39.6% | N/A |
| Current Ratio | 0.34-0.2x | 0.54-0.3x | 0.81+0.4x | 0.43-0.7x | 1.09+0.1x | 0.96-4.0x | 5.01-0.5x | 5.47+1.1x | 4.37-8.3x | 12.66 | N/A |
| Debt-to-Equity | 0.21 | N/A | N/A | N/A | 9.42+3.6x | 5.87 | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 4.94 | N/A | 10.14 | N/A | 19.42+7.4x | 12.00+11.8x | 0.230.0x | 0.22-0.1x | 0.27+0.1x | 0.18 | N/A |
| Asset Turnover | 0.01-0.4x | 0.45+0.2x | 0.28-0.1x | 0.39-0.1x | 0.47+0.1x | 0.36+0.3x | 0.080.0x | 0.13+0.1x | 0.07+0.1x | 0.00 | N/A |
| FCF Margin | -3376.2% | -116.6% | -548.7% | -47.5%+28.4pp | -76.0%+0.1pp | -76.1% | -650.4% | -412.5% | -1120.9% | -28062.4% | -594666.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.34), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Redhill Biopharma Ltd. RDHL | FY2025 | $286K | -$429K | N/A | $3.7M | — |
| Shuttle Pharmaceuticals Holdings, Inc. SHPH | FY2025 | N/A | -$11.7M | N/A | $24.0M | — |
| InMed Pharmaceuticals Inc. INM | FY2026 | N/A | -$12.6M | N/A | $8.7M | — |
| PRF Technologies Ltd. PRFX | FY2025 | $17K | -$5.0M | N/A | $2.6M | — |
| Sunshine Biopharma Inc. SBFM | FY2025 | $36.3M | -$6.0M | -16.5% | N/A | 60/100 |
| cbdMD, Inc. YCBD | FY2025 | $19.2M | -$2.0M | -10.6% | $4.1M | 47/100 |
Where Redhill Biopharma Ltd. Ranks
Frequently Asked Questions
What is Redhill Biopharma Ltd.'s annual revenue?
Redhill Biopharma Ltd. (RDHL) reported $286K in total revenue for fiscal year 2025. This represents a -96.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Redhill Biopharma Ltd.'s revenue growing?
Redhill Biopharma Ltd. (RDHL) revenue declined by 96.4% year-over-year, from $8.0M to $286K in fiscal year 2025.
Is Redhill Biopharma Ltd. profitable?
No, Redhill Biopharma Ltd. (RDHL) reported a net loss of $429K in fiscal year 2025.
How much debt does Redhill Biopharma Ltd. have?
As of fiscal year 2025, Redhill Biopharma Ltd. (RDHL) had $4.0M in cash and equivalents against $900K in long-term debt.
What is Redhill Biopharma Ltd.'s return on equity (ROE)?
Redhill Biopharma Ltd. (RDHL) has a return on equity of -10.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Redhill Biopharma Ltd.'s free cash flow?
Redhill Biopharma Ltd. (RDHL) recorded an outflow of $9.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Redhill Biopharma Ltd.'s operating cash flow?
Redhill Biopharma Ltd. (RDHL) recorded an outflow of $9.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Redhill Biopharma Ltd.'s total assets?
Redhill Biopharma Ltd. (RDHL) had $25.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Redhill Biopharma Ltd.'s capital expenditures?
Redhill Biopharma Ltd. (RDHL) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Redhill Biopharma Ltd.'s current ratio?
Redhill Biopharma Ltd. (RDHL) had a current ratio of 0.34 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Redhill Biopharma Ltd.'s debt-to-equity ratio?
Redhill Biopharma Ltd. (RDHL) had a debt-to-equity ratio of 0.21 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Redhill Biopharma Ltd.'s liabilities-to-equity ratio?
Redhill Biopharma Ltd. (RDHL) had a liabilities-to-equity ratio of 4.94 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Redhill Biopharma Ltd.'s return on assets (ROA)?
Redhill Biopharma Ltd. (RDHL) had a return on assets of -1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Redhill Biopharma Ltd.'s P/E ratio?
Redhill Biopharma Ltd. (RDHL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.7M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Redhill Biopharma Ltd.'s price-to-sales ratio?
Redhill Biopharma Ltd. (RDHL) trades at 12.9x sales, its market capitalization divided by $286K revenue, FY2025. The market capitalization is $3.7M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Redhill Biopharma Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Redhill Biopharma Ltd. (RDHL) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Redhill Biopharma Ltd.'s Piotroski F-Score?
Redhill Biopharma Ltd. (RDHL) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Redhill Biopharma Ltd.'s earnings high quality?
Redhill Biopharma Ltd. (RDHL) reported a net loss of $429K while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.